Login / Signup

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.

Jingwen SongYunzhong YangFranck Mauvais-JarvisYu-Ping WangTianhua Niu
Published in: BMC medical genetics (2017)
Our study indicates that a personalized medicine approach by tailoring sulfonylurea therapy of T2D patients according to their genotypes of KCNJ11, ABCC8, and TCF7L2 could attain an optimal treatment efficacy.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • combination therapy
  • mesenchymal stem cells
  • bone marrow
  • patient reported outcomes